| Diabetes Mellitus, Non-Insulin-Dependent
Onglyza vs Tradjenta
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Onglyza vs Tradjenta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTradjenta has a higher rate of injection site reactions vs Onglyza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tradjenta but not Onglyza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Onglyza
Tradjenta
At A Glance
Oral
Daily
DPP-4 inhibitor
Oral
Daily
DPP-4 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent 2.5 mg or 5 mg orally once daily taken regardless of meals; reduce to 2.5 mg once daily for eGFR <45 mL/min/1.73 m2 or when coadministered with strong CYP3A4/5 inhibitors.
Diabetes Mellitus, Non-Insulin-Dependent 5 mg orally once daily, with or without food.
Contraindications
- History of serious hypersensitivity reaction to saxagliptin or any ingredient in ONGLYZA (anaphylaxis, angioedema, or exfoliative skin conditions)
- Hypersensitivity to linagliptin or any excipient in TRADJENTA, including reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache
Serious Pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid
Most common (>=2%) Nasopharyngitis, diarrhea, cough
Serious Pancreatitis, hypoglycemia with concomitant insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid, rash
Pharmacology
Saxagliptin is a competitive DPP-4 inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus.
DPP-4 inhibitor; linagliptin reversibly inhibits DPP-4, the enzyme that degrades incretin hormones GLP-1 and GIP, thereby increasing active incretin concentrations, stimulating glucose-dependent insulin release from pancreatic beta cells, and reducing glucagon secretion from pancreatic alpha-cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Onglyza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Tradjenta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Onglyza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Tradjenta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Onglyza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Tradjenta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Onglyza.
No savings programs available for Tradjenta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OnglyzaView full Onglyza profile
TradjentaView full Tradjenta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.